PT  - JOURNAL ARTICLE
AU  - Nathan A. Painter
AU  - Candis M. Morello
AU  - Renu F. Singh
AU  - Sarah E. McBane
TI  - An Evidence-Based and Practical Approach to Using Bydureon™ in Patients With Type 2 Diabetes
AID  - 10.3122/jabfm.2013.02.120174
DP  - 2013 Mar 01
TA  - The Journal of the American Board of Family
                Medicine
PG  - 203--210
VI  - 26
IP  - 2
4099  - http://www.jabfm.org/content/26/2/203.short
4100  - http://www.jabfm.org/content/26/2/203.full
SO  - J Am Board Fam Med2013 Mar 01; 26
AB  - Glucagon-like peptide (GLP)-1 agonists are one of the newer classes of medications for use in type 2 diabetes. There are currently three GLP-1 agonists on the market: exenatide twice daily, liraglutide, and exenatide extended release (ER). Exenatide ER is a new weekly formulation of exenatide. Exenatide ER reduces glycosylated hemoglobin by 1.6%, with fewer gastrointestinal side effects compared with twice-daily exenatide. Like other GLP-1 agonists, exenatide ER can be used in combination with metformin, sulfonylureas, or thiazolidinediones. Patients should be assessed for risk of pancreatitis and renal impairment. Education about proper administration technique is vital with the novel delivery system. Prescribers may also consider the use of exenatide ER to improve medication adherence in patients who have successfully tolerated exenatide twice daily or use in patients who have gastrointestinal side effects with exenatide twice daily. Exenatide is a reasonable option that can be added to the regimen of a patient with type 2 diabetes.